$5.59
1.06% yesterday
Nasdaq, Nov 07, 10:09 pm CET
ISIN
US0396971071
Symbol
ARDX

Ardelyx, Inc. Stock price

$5.59
+0.42 8.12% 1M
+1.89 51.08% 6M
+0.52 10.26% YTD
-0.79 12.38% 1Y
+4.19 299.29% 3Y
-0.03 0.53% 5Y
-13.53 70.76% 10Y
-8.52 60.38% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.06 1.06%
ISIN
US0396971071
Symbol
ARDX
Industry

New AI Insights on Ardelyx, Inc. Insights AI Insights on Ardelyx, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.3b
Net debt
positive
Cash
$242.7m
Shares outstanding
243.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | 3.5
EV/Sales
3.4 | 3.4
EV/FCF
negative
P/B
8.9
Financial Health
Equity Ratio
39.8%
Return on Equity
-22.6%
ROCE
-9.4%
ROIC
-17.7%
Debt/Equity
1.3
Financials (TTM | estimate)
Revenue
$398.2m | $396.7m
EBITDA
$-35.3m | $-31.5m
EBIT
$-38.0m | $-60.4m
Net Income
$-56.6m | $-76.7m
Free Cash Flow
$-55.0m
Growth (TTM | estimate)
Revenue
58.1% | 18.9%
EBITDA
43.5% | -21.5%
EBIT
41.1% | -116.0%
Net Income
21.6% | -95.9%
Free Cash Flow
14.4%
Margin (TTM | estimate)
Gross
88.2%
EBITDA
-8.9% | -7.9%
EBIT
-9.5%
Net
-14.2% | -19.3%
Free Cash Flow
-13.8%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
8.9%
Employees
395
Rev per Employee
$840.0k
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
398 398
58% 58%
100%
- Direct Costs 47 47
25% 25%
12%
351 351
64% 64%
88%
- Selling and Administrative Expenses 327 327
42% 42%
82%
- Research and Development Expense 62 62
29% 29%
16%
-35 -35
44% 44%
-9%
- Depreciation and Amortization 2.65 2.65
39% 39%
1%
EBIT (Operating Income) EBIT -38 -38
41% 41%
-10%
Net Profit -57 -57
22% 22%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Neutral
GlobeNewsWire
about 7 hours ago
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study of XPHOZAH, at American Society of Nephrology's ...
Neutral
GlobeNewsWire
3 days ago
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November ...
Positive
Seeking Alpha
3 days ago
Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing comm...
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 395
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today